Celularity
Develops placenta-derived cell therapies for longevity and age-related disease.
Something off on this page? Send us feedback.
Profile
Develops and manufactures allogeneic and autologous cell therapies derived from postpartum placenta. It refocused on longevity and cell-therapy platforms after out-licensing its biomaterials portfolio.
Develops and manufactures allogeneic and autologous cell therapies derived from postpartum placenta, with a current focus on longevity and cell-therapy platforms. Its development portfolio includes MLASC candidates PDA-001 and PDA-002, plus the CYNK-001 and CYNK-101 natural-killer-cell platforms.
Those programs address Crohn’s disease, diabetic foot ulcer, facioscapulohumeral muscular dystrophy, solid tumors, autoimmune disease, and cancer combinations. Placental T-cell work includes allogeneic cells with CAR expression and knockout of endogenous T-cell receptors.
Headquartered in Florham Park, New Jersey, the company out-licensed its biomaterials portfolio to concentrate resources on cell therapy and longevity. Its development model depends on postpartum placenta as an ethically sourced, scalable biological input; the named programs are development platforms, not approved therapies.
Company facts
Key statistics
Year to date +29.8% · Average volume (30d) 7.9M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating |
|---|---|---|---|---|
| Sep 9, 2025 | WBB Securities | Upgrade | Hold | Buy |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| May 8, 2026 | — | −$0.59 | — | — | — | — | −12.49% |
| Apr 30, 2026 | −$1.50 | −$0.95 | +36.7% | $4.1M | $4.1M | 0.0% | +2.43% |
| Nov 14, 2025Q3 FY25 | −$1.50 | −$0.88 | +41.3% | — | $5.3M | — | −1.94% |
| Aug 29, 2025Q2 FY25 | — | −$0.84 | — | — | $11.4M | — | −35.28% |
Financial highlights
| 12 quarters | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | |
|---|---|---|---|---|---|---|---|
| Revenue | $9.3M | $18.1M | $11.4M | $5.7M | $5.3M | $4.1M | |
| Gross profit | $5.4M | $10.8M | $7.9M | $494.0K | $3.3M | $8.6M | |
| Operating income | −$11.5M | −$9.3M | −$10.5M | −$15.9M | −$12.9M | −$22.1M | |
| Net income | −$16.1M | −$13.3M | −$19.8M | −$24.5M | −$23.1M | −$24.4M | |
| Diluted EPS | −$0.73 | −$0.59 | −$0.84 | −$1.02 | −$0.88 | −$0.95 | |
| Gross margin | 58.2% | 59.5% | 68.9% | 8.6% | 61.8% | 208.5% | |
| Operating margin | -124.0% | -51.2% | -91.8% | -276.6% | -244.1% | -537.5% |
Fiscal years (4-quarter sums)FY21 $21.3M · FY22 $18.0M · FY23 $22.8M · FY24 $54.2M · FY25 $26.6M
Revenue by product · Q4 FY25
Balance sheet, Dec 31, 2025Cash & short-term investments $6.2M · Total debt $40.9M · Total assets $107.3M · Shareholders' equity −$38.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 28.95M · Float 18.87M · 65.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Lim Kok Thay | 14.14M | 41.00% | 13D | Jul 28, 2025 |
| Philip & Daniele Barach Family Trust | 5.51M | 15.80% | 13D | Jun 23, 2026 |
| Philp & Daniele Barach Family Trust | 3.01M | 9.56% | 13D | Apr 3, 2026 |
| Robert J. Hariri · director, officer: Chief Executive Officer | 2.85M | 9.86% | Form 4 | Apr 15, 2026 |
| C V Starr & Co Inc | 764.1K | 2.64% | 13F | Aug 11, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Pluri
Placenta-derived allogeneic stromal-cell therapies for regeneration
- Allogene Therapeutics
Off-the-shelf allogeneic CAR-T for cancer and autoimmune disease
- Fate
iPSC-derived off-the-shelf CAR-T and NK-cell programs
- Nkarta
Engineered allogeneic CAR-NK therapies for autoimmune disease
- Century Therapeutics
iPSC-derived allogeneic therapies for autoimmune disease and cancer
- Mesoblast (ADR)
Allogeneic stromal-cell medicines for inflammatory disease
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Celularity | $1.48 | −5.63% | $45.7M | — | — | 1.7 | −77.4% |
| Pluri | $1.53 | +2.00% | $16.5M | — | — | 15.3 | −60.9% |
| Allogene Therapeutics | $2.01 | −0.09% | $697.2M | — | — | 150.3 | — |
| Fate | $2.43 | +0.60% | $283.2M | — | — | 43.6 | +9.2% |
| Nkarta | $2.80 | +1.45% | $197.5M | — | — | — | — |
| Century Therapeutics | $2.03 | +0.25% | $175.3M | — | — | — | — |
| Mesoblast (ADR) | $17.44 | −0.17% | $2.26B | — | — | 35.0 | +882.8% |
| Median | — | — | 39.3 | +9.2% |